The current treatments for advanced ccRCC are VEGF, VEGFR and mammalian target of rapamycin (mTOR) (Wang et al., 2018) – targeted therapy, but surgical treatment remains the most effective clinical therapy for ccRCC. Here, VEGFA is linked to nonpapillary renal cell carcinoma.